CUE BIOPHARMA

NASDAQ: CUE (Cue Biopharma, Inc.)

Last update: 2 hours ago

7.87

-6.23 (-44.18%)

Previous Close 14.10
Volume 559,118
Price / Sales 1.94
Price / Book 36.54
52 Weeks Range
4.98 (-36%) — 45.50 (478%)
Operating Margin (TTM) -2,921.38%
Diluted EPS (TTM) -0.640
Quarterly Revenue Growth (YOY) -75.50%
Total Debt/Equity (MRQ) 108.28%
Current Ratio (MRQ) 1.03
Operating Cash Flow (TTM) -34.72 M
Levered Free Cash Flow (TTM) -18.34 M
Return on Assets (TTM) -67.62%
Return on Equity (TTM) -221.66%

AIStockmoo Score

-2.4
Value 30% -4.2
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Weak profitability. Thin short-term liquidity. Negative cash flow. info
Earns below its cost of capital. Returns on capital falling. info
Timing 30% -3.6
From our AI technical analysis of the chart. info NA
No clear trend over the past year. Far below its 52-week high. info
Candle Patterns info NA
Trend for Your Holding Period info NA
Sentiment 20% 0.0
No recent price targets, so based on how targets have been revised. info
News Mood info NA
Smart Money 20% 1.9
Insider Activity info NA
Institutions net +75.12% of shares in their latest 13F filings: 35 holders increased, 19 decreased (quarter to 30 Sep 2026). info
Short interest +171.0% from 31 Aug to 30 Oct 2026, 7.6 days to cover (FINRA). info
Market and sector conditions are poor.
Market environment cautious. info
Sector lagging the market.
The pillars agree, so the score is strengthened.
Not in score
Price is low against its 52-week average. Down over 5 years. info
Trend down on all three terms. Short-term momentum falling. info
No clear signal from support and resistance. info
Final Score -2.43

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Cue Biopharma, Inc. Mixed Mixed

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
CUE - - - 36.54
TRML 1 B - - 4.76
CTMX - - - 1.55
HURA - - - 4.84
GANX - - - 4.54
PRTA - - - 1.56

Select this tab to load the latest available analysis.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Sector Healthcare
Industry Biotechnology
Investment Style Small Core
% Held by Insiders 0.35%
% Held by Institutions 19.45%

Ownership

Name Date Shares Held
Tetragon Partners Gp Ltd 30 Jun 2026 93,819

No data within this time range.

No data within this time range.

Institutions

Institutional ownership: 65.83%

Positions Holders Shares
Increased 35 3,280,294
Decreased 19 254,853
New 17 2,454,175
Sold out 8 221,057

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 862,798 7.6
15 Oct 2026 792,553 3.7
30 Sep 2026 702,198 1.1
15 Sep 2026 332,105 2.4
31 Aug 2026 318,420 1.8
14 Aug 2026 327,442 1.6

FINRA short interest via Nasdaq, reported twice a month.

1 Positive 0 Negative 0 Neutral
Date Type Details
16 Nov 2026 Yahoo Finance Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
CUE-221 Phase 2 chronic spontaneous urticaria (CSU) findings highlight differentiated clinical benefit and potential to expand the addressable patient population in CSU and food allergy CUE-401 enters clinical development with initiation of first-in-human dosing, achieving key 2026 milestone…
28 Sep 2026 Yahoo Finance Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response
Cue Biopharma (NASDAQ:CUE) reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines. The randomized, double-blind, placebo-controlled study evaluate…
25 Sep 2026 Yahoo Finance Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?
Cue Biopharma, Inc. (NASDAQ:CUE) reported positive Phase 2 results for CUE-221 on September 20. The randomized, double-blind study enrolled 145 patients in China with moderate to severe chronic spontaneous urticaria, or chronic hives, inadequately controlled by H1 antihistamines. At week 12…
22 Sep 2026 Yahoo Finance An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.
21 Sep 2026 Yahoo Finance Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results
Cue Biopharma (NASDAQ:CUE) shares rose 41. 6% in premarket trading after the company reported positive topline results from a Phase 2 clinical trial evaluating CUE-221 in patients with moderate to severe chronic spontaneous urticaria.
20 Sep 2026 Yahoo Finance Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling studyPrimary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable…

Recent Signals candle patterns and EMA crosses

▼ Death cross 8 sessions ago · 04 Nov
Long term · EMA 50/200
The 50-day EMA crossed below the 200-day, a widely watched sign that the long-term trend has turned down.

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria